Brief: Revolution Medicines Announces Closing Of Concurrent Upsized Public Offerings With Aggregate Gross Proceeds Of Approximately $2.2 Billion, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares
17/04/2026 21:36
April 17 (Reuters) - Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES ANNOUNCES CLOSING OF CONCURRENT UPSIZED PUBLIC OFFERINGS WITH AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $2.2 BILLION, INCLUDING FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Source text: ID:nGNX1fGjmp Further company coverage: RVMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns